Zasocitinib (TAK-279) - (LATITUDE PsO)

June 23, 2026: Takeda Canada Inc. (Takeda Pharmaceutical Company Limited; NYSE: TAK) reported positive topline results from the Phase 3 LATITUDE Atlas (TAK-279-PsO-3004; NCT06973291) randomized, double-blind head-to-head trial of once-daily oral zasocitinib (TAK-279), a selective TYK2 inhibitor, versus deucravacitinib in adults with moderate-to-severe plaque psoriasis.

Zasocitinib showed statistical superiority over deucravacitinib on the primary endpoint (PASI 100 at week 16) and all key secondary endpoints, including PASI 90 and sPGA 0 at week 16. More than 35% of zasocitinib-treated patients achieved PASI 100 at week 16, described as more than 2.5x the response rate with deucravacitinib. Safety and tolerability were consistent with prior studies, with no new safety signals.

Trial details: 606 participants across eight countries (including 73 patients at 18 Canadian sites); dosing was zasocitinib 30 mg QD vs deucravacitinib 6 mg QD through week 16.

Next steps: Takeda plans to present detailed data at upcoming medical congresses and is on track to begin submitting an NDA for plaque psoriasis to the FDA and other regulators starting this fiscal year.